Abstract | OBJECTIVES: METHODS: The parotid and submandibular glands of 10 patients were injected with BTX-A using ultrasound guidance. Before injection, the baseline rate of salivation was assessed using a visual analogue scale. Postinjection, assessments were repeated at regular intervals for up to 1 year. RESULTS: Of the 10 patients treated, nine (90%) reported a subjective reduction in salivation post-treatment and one patient (10%) found no improvement. Visual analogue scale scores showed a reduction of 55% in the mean rate of salivation for all patients and a reduction of 60.8% for the group of responders. No serious adverse events occurred and no procedure related complications were reported. CONCLUSIONS: This is the first study to report (1) the injection of BTX-A ( BOTOX) into both parotid and submandibular glands, and (2) the use of ultrasound guidance during the administration of BTX-A into salivary glands. The results suggest that the technique is safe and that BTX-A injections are effective for the treatment of sialorrhoea in patients with neurological disorders.
|
Authors | M Porta, M Gamba, G Bertacchi, P Vaj |
Journal | Journal of neurology, neurosurgery, and psychiatry
(J Neurol Neurosurg Psychiatry)
Vol. 70
Issue 4
Pg. 538-40
(Apr 2001)
ISSN: 0022-3050 [Print] England |
PMID | 11254784
(Publication Type: Journal Article)
|
Chemical References |
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Botulinum Toxins, Type A
(therapeutic use)
- Humans
- Middle Aged
- Nervous System Diseases
(complications)
- Sialorrhea
(complications, drug therapy)
- Ultrasonography, Interventional
|